Blood test may spot hidden breast cancer months before scans
NCT ID NCT07478705
First seen Mar 22, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This study tests whether regular blood tests (ctDNA) can find triple-negative breast cancer recurrence earlier than standard follow-up. Thirty patients who had surgery for stage II or III TNBC will be randomly assigned to either standard care or standard care plus ctDNA testing every 3 months. If the blood test shows signs of cancer, they will get extra scans. The goal is to see if this approach is practical for a larger future trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ctDNA blood test
What this could lead to
If successful, this approach could help detect cancer return months earlier, potentially leading to better treatment outcomes and longer survival for patients with triple-negative breast cancer.
What could go wrong
This is a very small pilot study (30 people) testing feasibility, not yet proving that earlier detection improves survival. It may not lead to clear benefits and could cause unnecessary anxiety or scans.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.